Some Love for Express Scripts

By Paul Price 

ESRX logo

Express Scripts (ESRX) is a double-dip holding in Market Shadows’ Virtual Value Portfolio - i.e. we averaged down on it.

Some news:

On March 14, a director of ESRX bought 5,000 shares in the company for $297,925 ($59.585 /share).

Value Line reviewed ESRX in its new March 22 issue. According to Value Line, Express Scripts is performing well. Industry conditions remain favorable and merger benefits from the April 2012 Medco acquisition are still building up.

The company has a good balance sheet. GAAP EPS, which dipped to $1.79 last year, are expected to reach $2.80 in 2013. Value Line sees $5.30 per share in profits over the next 3 – 5 years. Its long term target price projection centers on $117.50. That’s almost double the March 18 closing quote of $59.54.

 

Did you like this? Share it:

Subscribe

Trackbacks

  1. [...] sees less bargains than he did several months ago. However, he still likes Express Scripts (ESRX), Quest Diagnostics (DGX), Lab Corp. (LH), Coach Inc. (COH) and Calamos Asset Management Inc. [...]

  2. [...] Price sees less bargains than he did several months ago. However, he still likes Express Scripts (ESRX), Quest Diagnostics (DGX), Lab Corp. (LH), Coach Inc. (COH) and Calamos Asset Management Inc. [...]

Speak Your Mind

*


*

%d bloggers like this: